Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi.
Equine airways represent a suitable ex vivo model to study the functional impact of pharmacological treatments on human chronic obstructive pulmonary disorders, such as asthma and chronic obstructive pulmonary disease (COPD). We aimed to characterize the pharmacological interaction between the long-acting muscarinic antagonist (LAMA) tiotropium and the long-acting β2-agonist (LABA) olodaterol in equine airways. The effect of tiotropium and olodaterol, administered alone and in combination at the ratio of concentrations reproducing ex vivo the concentration-ratio delivered by the currently available fixed-dose combination (FDC) (5:5), was investigated on the cholinergic contractile tone induced by the parasympathetic activation of equine isolated airways. The drug interaction was analysed by using the Bliss Independence and Unified Theory models. Both tiotropium and olodaterol induced a sub-maximal concentration-dependent inhibition of bronchial contractility (Emax: tiotropium 83.6 ± 14.8%, olodaterol 76.9 ± 17.9%; pEC50: tiotropium 8.2 ± 0.5; olodaterol 8.3 ± 0.6). When administered at 5:5 concentration-ratio, tiotropium plus olodaterol completely inhibited the bronchial contractility (Emax 102.7 ± 8.4%; pEC50 9.0 ± 0.7). Strong synergistic interaction was detected for tiotropium/olodaterol combination (combination index 0.011). When administered at low concentrations, the drug mixture elicited up to 94.6 ± 9.5% effect that was 36.0 ± 8.1% greater than the expected additive effect. The results of this study demonstrate that the co-administration of tiotropium plus olodaterol at 5:5 concentration-ratio leads to synergistic inhibition of equine bronchial contractility when compared with either drug administered alone. These findings suggest that the currently available LABA/LABA FDC may be effective in delivering tiotropium/olodaterol combination at equipotency concentrations of each monocomponent into the lung and, thus, inducing synergistic effect in the airways.
['Calzetta|Luigino|L|http://orcid.org/0000-0003-0456-069X', 'Rogliani|Paola|P|http://orcid.org/0000-0001-7801-5040', 'Mattei|Maurizio|M|http://orcid.org/0000-0002-0814-8873', 'Alfonsi|Pietro|P|', 'Cito|Giuseppe|G|', 'Pistocchini|Elena|E|', 'Cazzola|Mario|M|http://orcid.org/0000-0003-4895-9707', 'Matera|Maria Gabriella|MG|http://orcid.org/0000-0002-5113-9235']
D058666:Adrenergic beta-2 Receptor Agonists D000818:Animals D048588:Benzoxazines D001980:Bronchi D001993:Bronchodilator Agents D004305:Dose-Response Relationship, Drug D004357:Drug Synergism D005260:Female D006736:Horses D008297:Male D018727:Muscarinic Antagonists D009119:Muscle Contraction D009130:Muscle, Smooth D000069447:Tiotropium Bromide
tiotropium olodaterol Equine fixed-dose combination synergistic interaction isolated bronchi recurrent airway obstruction